Christopher L Bowlus

List of Publications by Citations

186 papers	8,073 citations	48 h-index	84 g-index
225 ext. papers	9,607 ext. citations	7.5 avg, IF	5.94 L-index

#	Paper	IF	Citations
186	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Current Medical Research and Opinion*, **2008**, 24, 275-86	2.5	591
185	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *New England Journal of Medicine*, **2016**, 375, 631-43	59.2	574
184	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, **2013**, 45, 670-5	36.3	267
183	Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. *Hepatology*, **2006**, 43, 729-37	11.2	244
182	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. *Clinical Therapeutics*, **2007**,	3.5	235
181	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*, **2019**, 69, 394-419	11.2	224
180	Primary biliary cirrhosis. *Lancet, The*, **2011**, 377, 1600-9	40	220
179	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*, **2017**, 152, 1975-1984.e8	13.3	219
178	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Current Medical Research and Opinion*, **2008**, 24, 275-286	2.5	217
177	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. *Hepatology*, **2010**, 52, 987-98	11.2	154
176	IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. *Journal of Autoimmunity*, **2006**, 27, 50-3	15.5	147
175	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. *Nature Genetics*, **2017**, 49, 269-273	36.3	140
174	De novo nonalcoholic fatty liver disease after liver transplantation. *Liver Transplantation*, **2007**, 13, 844-7	4.5	140
173	IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. *Hepatology*, **2014**, 59, 1944-53	11.2	137
172	DMT1 gene expression and cadmium absorption in human absorptive enterocytes. *Toxicology Letters*, **2001**, 122, 171-7	4.4	123
171	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. *Hepatology*, **2012**, 55, 512-21	11.2	107
170	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. *Hepatology*, **2019**, 70, 788-801	11.2	101

169	The diagnosis of primary biliary cirrhosis. *Autoimmunity Reviews*, **2014**, 13, 441-4	13.6	101
168	Cloning and analysis of the promotor region of the human fibronectin gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 1876-80	11.5	91
167	T cell immunity in autoimmune hepatitis. *Autoimmunity Reviews*, **2005**, 4, 315-21	13.6	89
166	The geoepidemiology of autoimmune intestinal diseases. *Autoimmunity Reviews*, **2010**, 9, A372-8	13.6	88
165	Seladelpar (MBX-8025), a selective PPAR- agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 716-726	18.8	81
164	Transforming growth factor beta (TGF-beta) and autoimmunity. *Autoimmunity Reviews*, **2005**, 4, 450-9	13.6	81
163	Costs of hepatitis C. *Archives of Internal Medicine*, **2001**, 161, 2231-7		76
162	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 445-453	18.8	73
161	Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. *Seminars in Immunopathology*, **2009**, 31, 309-22	12	72
160	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. *Hepatology*, **2019**, 69, 684-698	11.2	71
159	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. *Clinical Gastroenterology and Hepatology*, **2005**, 3, 390-6	6.9	70
158	The role of iron in T cell development and autoimmunity. *Autoimmunity Reviews*, **2003**, 2, 73-8	13.6	70
157	B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. *Gastroenterology*, **2009**, 136, 1037-47	13.3	69
156	The immunobiology of primary sclerosing cholangitis. *Seminars in Immunopathology*, **2009**, 31, 383-97	12	67
155	Evaluation of indeterminate biliary strictures. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 28-37	24.2	64
154	The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. *BMC Gastroenterology*, **2011**, 11, 83	3	64
153	Etiopathogenesis of autoimmune hepatitis. *Journal of Autoimmunity*, **2018**, 95, 133-143	15.5	62
152	IL-35 and Autoimmunity: a Comprehensive Perspective. *Clinical Reviews in Allergy and Immunology*, **2015**, 49, 327-32	12.3	61

151	The immunobiology of primary sclerosing cholangitis. *Autoimmunity Reviews*, **2005**, 4, 137-43	13.6	61
150	Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. *Hepatology*, **2014**, 60, 1708-16	11.2	59
149	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. *Clinical and Experimental Immunology*, **2016**, 185, 61-71	6.2	59
148	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. *Journal of Hepatology*, **2020**, 73, 94-101	13.4	57
147	Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. *Journal of Clinical Gastroenterology*, **2005**, 39, 71-4	3	56
146	Iron supplementation during infancy--effects on expression of iron transporters, iron absorption, and iron utilization in rat pups. *American Journal of Clinical Nutrition*, **2003**, 78, 1203-11	7	55
145	Functional and molecular responses of human intestinal Caco-2 cells to iron treatment. *American Journal of Clinical Nutrition*, **2000**, 72, 770-5	7	54
144	Cloning of a novel MHC-encoded serine peptidase highly expressed by cortical epithelial cells of the thymus. *Cellular Immunology*, **1999**, 196, 80-6	4.4	51
143	S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. *Alcoholism: Clinical and Experimental Research*, **2011**, 35, 1960-5	3.7	50
142	Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. *Liver Transplantation*, **2010**, 16, 1324-30	4.5	50
141	T cell immunity and graft-versus-host disease (GVHD). *Autoimmunity Reviews*, **2006**, 5, 1-9	13.6	50
140	Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. *Journal of Hepatology*, **2010**, 53, 551-7	13.4	49
139	Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. *Liver International*, **2015**, 35, 642-51	7.9	48
138	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. *Hepatology*, **2011**, 54, 196-203	11.2	48
137	DMT1 and FPN1 expression during infancy: developmental regulation of iron absorption. *American Journal of Physiology - Renal Physiology*, **2003**, 285, G1153-61	5.1	48
136	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. *Hepatology*, **2003**, 38, 1018-1025	11.2	48
135	Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 782-91	4	47
134	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. *Hepatology*, **2013**, 57, 1498-508	11.2	46

133	Revisiting hereditary hemochromatosis: current concepts and progress. *American Journal of Medicine*, **2006**, 119, 391-9	2.4	46
132	Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. *Journal of Gastroenterology*, **2006**, 41, 1053-63	6.9	46
131	The challenges of primary biliary cholangitis: What is new and what needs to be done. *Journal of Autoimmunity*, **2019**, 105, 102328	15.5	45
130	A transcription map of the major histocompatibility complex (MHC) class I region. *Genomics*, **1996**, 36, 70-85	4.3	45
129	Diagnosis and classification of primary sclerosing cholangitis. *Autoimmunity Reviews*, **2014**, 13, 445-50	13.6	42
128	Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. *Hepatology*, **2011**, 54, 1293-302	11.2	42
127	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1342-1350.e1	6.9	40
126	Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization. *Biological Psychiatry*, **1998**, 44, 659-66	7.9	40
125	Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. *Clinical Reviews in Allergy and Immunology*, **2015**, 48, 132-41	12.3	39
124	Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. *Journal of Gastroenterology*, **2006**, 41, 954-61	6.9	39
123	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1170-1178.e6	6.9	39
122	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. *Cellular and Molecular Immunology*, **2017**, 14, 276-284	15.4	37
121	The evolution of natural history of primary sclerosing cholangitis. *Current Opinion in Gastroenterology*, **2017**, 33, 71-77	3	37
120	Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. *Digestive Diseases and Sciences*, **2013**, 58, 807-14	4	36
119	Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. *World Journal of Gastroenterology*, **2016**, 22, 8584-8595	5.6	36
118	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. *Clinical and Experimental Immunology*, **2013**, 174, 364-71	6.2	35
117	Effect of iron treatment on nickel absorption and gene expression of the divalent metal transporter (DMT1) by human intestinal Caco-2 cells. *Basic and Clinical Pharmacology and Toxicology* , **2003**, 92, 121-4		33
116	Common Variable Immunodeficiency and Liver Involvement. *Clinical Reviews in Allergy and Immunology*, **2018**, 55, 340-351	12.3	32

115	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2416-2422	6.9	31
114	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. *Hepatology Communications*, **2019**, 3, 365-381	6	30
113	New therapies for primary biliary cirrhosis. *Clinical Reviews in Allergy and Immunology*, **2015**, 48, 263-72	12.3	28
112	O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS. *Journal of Hepatology*, **2014**, 60, S525-S526	13.4	28
111	Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. *Pediatric Hematology and Oncology*, **2007**, 24, 237-43	1.7	28
110	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut*, **2018**, 67, 1517-1524	19.2	28
109	Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. *Journal of Immunology*, **2013**, 191, 2126-33	5.3	27
108	Anti-mitochondrial antibody-negative primary biliary cirrhosis. *Clinics in Liver Disease*, **2008**, 12, 173-85, ix	4.6	27
107	Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017. *Morbidity and Mortality Weekly Report*, **2018**, 67, 541-546	31.7	27
106	Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. *Hepatic Medicine: Evidence and Research*, **2016**, 8, 89-95	3.4	27
105	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). *Autoimmunity Reviews*, **2016**, 15, 795-800	13.6	27
104	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. *Clinical Reviews in Allergy and Immunology*, **2018**, 54, 282-294	12.3	26
103	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1333-1341.e6	6.9	26
102	Transcription profile of Helicobacter pylori in the human stomach reflects its physiology in vivo. *Journal of Infectious Diseases*, **2004**, 190, 946-56	7	26
101	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. *Journal of Autoimmunity*, **2019**, 101, 26-34	15.5	25
100	Advances in pharmacotherapy for primary biliary cirrhosis. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 633-43	4	25
99	T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. *Journal of Autoimmunity*, **2011**, 37, 71-8	15.5	24
98	Quality of life and everyday activities in patients with primary biliary cirrhosis. *Hepatology*, **2007**, 46, 1836-43	11.2	24

97	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 179-187.e6	6.9	24
96	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. *Epigenetics and Chromatin*, **2019**, 12, 10	5.8	23
95	The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. *Clinical Reviews in Allergy and Immunology*, **2012**, 43, 230-41	12.3	23
94	Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. *Hepatology*, **2017**, 66, 885-895	11.2	21
93	Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches. *Clinics in Liver Disease*, **2016**, 20, 67-77	4.6	20
92	Immunological orchestration of liver fibrosis. *Clinical Reviews in Allergy and Immunology*, **2012**, 43, 220-9	12.3	20
91	Effect of penicillamine and zinc on iron metabolism in Wilson's disease. *Scandinavian Journal of Gastroenterology*, **2007**, 42, 1495-500	2.4	20
90	Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. *Journal of Hepatology*, **2006**, 45, 704-10	13.4	20
89	Obesity in BSB mice is correlated with expression of genes for iron homeostasis and leptin. *Obesity*, **2004**, 12, 191-204		20
88	The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. *Clinical Reviews in Allergy and Immunology*, **2017**, 52, 424-435	12.3	19
87	Primary sclerosing cholangitis: A review and update. *Liver Research*, **2017**, 1, 221-230	4.1	19
86	Cutting edge issues in primary sclerosing cholangitis. *Clinical Reviews in Allergy and Immunology*, **2011**, 41, 139-50	12.3	19
85	Ascorbic acid reduces the frequency of iron induced micronuclei in bone marrow cells of mice. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2003**, 542, 99-103	3	17
84	Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. *Journal of Managed Care & Specialty Pharmacy*, **2016**, 22, S3-S15	1.9	17
83	Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. *Clinical Reviews in Allergy and Immunology*, **2020**, 58, 134-149	12.3	17
82	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. *Journal of Hepatology*, **2018**, 69, 368-377	13.4	16
81	Polymorphisms in the gene encoding thymus-specific serine protease in the extended HLA complex: a potential candidate gene for autoimmune and HLA-associated diseases. *Genes and Immunity*, **2002**, 3, 306-12	4.4	16
80	Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice. *Journal of Nutrition*, **2004**, 134, 435-8	4.1	15

79	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. *Hepatology*, **2003**, 38, 1018-25	11.2	15
78	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. *Hepatology*, **2018**, 68, 155-165	11.2	14
77	Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. *Clinical and Experimental Immunology*, **2015**, 180, 371-82	6.2	13
76	Gene expression by PBMC in primary sclerosing cholangitis: evidence for dysregulation of immune mediated genes. *Clinical and Developmental Immunology*, **2006**, 13, 265-71		13
75	Geoepidemiology and changing mortality in primary biliary cholangitis. *Journal of Gastroenterology*, **2017**, 52, 655-662	6.9	12
74	Primary sclerosing cholangitis etiopathogenesis and clinical management. *Frontiers in Bioscience - Elite*, **2012**, E4, 1683-1705	1.6	11
73	Expression, genomic structure and mapping of the thymus specific protease prss16: a candidate gene for insulin dependent diabetes mellitus susceptibility. *Journal of Autoimmunity*, **2002**, 18, 311-6	15.5	11
72	FISH-Mapped CEPH YACs spanning 0 to 46 cM on human chromosome 6. *Genomics*, **1996**, 36, 104-11	4.3	11
71	RAR acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. *FASEB Journal*, **2019**, 33, 2314-2326	0.9	11
70	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. *Journal of Hepatology*, **2019**, 70, e1-e2	13.4	10
69	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 591-593	6.9	10
68	In situ mass spectrometry of autoimmune liver diseases. *Cellular and Molecular Immunology*, **2011**, 8, 237-42	15.4	10
67	Prss16 is not required for T-cell development. *Molecular and Cellular Biology*, **2005**, 25, 789-96	4.8	10
66	Primary sclerosing cholangitis: etiopathogenesis and clinical management. *Frontiers in Bioscience - Elite*, **2012**, 4, 1683-705	1.6	10
65	Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. *Clinical Reviews in Allergy and Immunology*, **2020**, 59, 175-194	12.3	10
64	Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. *Clinical and Experimental Immunology*, **2016**, 185, 154-64	6.2	10
63	Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 1372-1378	6.9	9
62	Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. *Journal of Hepatology*, **2018**, 68, S105-S106	13.4	9

61	Electronic Medical Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1352-1357	4	9
60	PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS. *Digestive and Liver Disease*, **2018**, 50, e67	3.3	9
59	Non-alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches. *Journal of Medicinal Food*, **2007**, 10, 563-5	2.8	9
58	Proposed therapies in primary biliary cholangitis. *Expert Review of Gastroenterology and Hepatology* , **2016**, 10, 371-382	4.2	8
57	The potentiating and protective effects of ascorbate on oxidative stress depend upon the concentration of dietary iron fed C3H mice. *Journal of Nutritional Biochemistry*, **2007**, 18, 272-8	6.3	8
56	Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis. *Digestive Diseases and Sciences*, **2016**, 61, 2776-2783	4	8
55	Granular cells as a marker of early amiodarone hepatotoxicity. *Journal of Clinical Gastroenterology*, **2000**, 31, 241-3	3	7
54	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. *Liver International*, **2021**,	7.9	7
53	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. *Hepatology Communications*, **2021**, 5, 478-490	6	7
52	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2020**, 115, 262-270	0.7	6
51	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. *Clinical Liver Disease*, **2020**, 15, 1-2	2.2	6
50	A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale. *Hepatology Communications*, **2018**, 2, 484-491	6	6
49	Prevalence of hepatitis B surface antigen in US-born and foreign-born Asian/Pacific Islander college students. *Journal of American College Health*, **2010**, 59, 37-41	2.2	6
48	Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. *Gastroenterology and Hepatology*, **2018**, 14, 154-163	0.7	6
47	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. *JHEP Reports*, **2020**, 2, 100060	10.3	6
46	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1248-1257	6.9	6
45	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2295-2304.e2	6.9	5
44	Management of symptom complexes in primary biliary cholangitis. *Current Opinion in Gastroenterology*, **2016**, 32, 204-9	3	5

43	Interim report of a randomized cross-over study comparing clinical performance of novice trainee endoscopists using conventional air insufflation versus warm water infusion colonoscopy. *Journal of Interventional Gastroenterology*, **2012**, 2, 135-139		5
42	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. *Liver Research*, **2019**, 3, 118-127	4.1	4
41	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. *Journal of Autoimmunity*, **2020**, 113, 102503	15.5	4
40	An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction. *Digestive and Liver Disease*, **2005**, 37, 206-10	3.3	4
39	Analysis of the IDDM candidate gene Prss16 in NOD and NON mice. *Autoimmunity*, **2002**, 9, 183-6		4
38	Scratching the surface of cholestatic itch treatments. *Hepatology*, **2018**, 67, 2045-2048	11.2	4
37	Current Treatment Options for Primary Biliary Cholangitis. *Clinics in Liver Disease*, **2018**, 22, 481-500	4.6	4
36	Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. *Free Radical Biology and Medicine*, **2021**, 172, 490-502	7.8	4
35	Human β-Defensin 2 in Primary Sclerosing Cholangitis. *Clinical and Translational Gastroenterology*, **2017**, 8, e80	4.2	3
34	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. *Journal of Hepatology*, **2020**, 73, S464-S465	13.4	3
33	Electronic health record alerts enhance mass screening for chronic hepatitis B. *Scientific Reports*, **2020**, 10, 19153	4.9	3
32	Primary Biliary Cholangitis: A Brief Overview. *Clinical Liver Disease*, **2020**, 15, 100-104	2.2	3
31	Iron Metabolism and Related Disorders **2013**, 1-41		3
30	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.. *Journal of Hepatology*, **2022**,	13.4	3
29	FRI-037-Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort. *Journal of Hepatology*, **2019**, 70, e400	13.4	2
28	The use of biologics in the treatment of autoimmune liver disease. *Expert Opinion on Investigational Drugs*, **2020**, 29, 385-398	5.9	2
27	Primary biliary cholangitis: Diagnosis and treatment. *Liver Research*, **2018**, 2, 81-86	4.1	2
26	FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. *Journal of Hepatology*, **2019**, 70, e390-e391	13.4	2

25	Obeticholic acid for the treatment of primary biliary cirrhosis. *Expert Opinion on Orphan Drugs*, **2014**, 2, 1351-1358	1.1	2
24	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. *Hepatology*, **2021**, 73, 1105-1116	11.2	2
23	558 - International Experience of Vedolizumab in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. *Gastroenterology*, **2018**, 154, S-1097	13.3	2
22	Primary sclerosing cholangitis: One disease or several?. *Clinical Liver Disease*, **2014**, 3, 34-37	2.2	1
21	Cytoskeletal Autoantibodies/Antiactin Antibodies **2014**, 311-317		1
20	CYTOSKELETAL AUTOANTIBODIES/ANTI-ACTIN ANTIBODIES **2007**, 309-316		1
19	Discussion of the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease. *Gastroenterology*, **2003**, 124, 1562-3; author reply 1564	13.3	1
18	Epidemiology and Natural History of Primary Sclerosing Cholangitis **2017**, 1-11		1
17	Healthcare Disparities Identified Between Hmong and Other Asian Origin Groups Living with Chronic Hepatitis B Infection in Sacramento County 2014-2017. *Journal of Community Health*, **2020**, 45, 412-418	4	1
16	Role of Antinuclear Antibodies in Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2020**, 115, 1604-1606	0.7	1
15	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	1
14	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. *Digestive Diseases and Sciences*, **2021**, 1	4	1
13	Primary Biliary Cholangitis **2020**, 335-357		0
12	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. *Gastroenterology*, **2021**, 161, 1764-1775.e5	13.3	0
11	Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. *Clinical Immunology*, **2021**, 230, 108825	9	0
10	Primary Biliary Cholangitis: Its Science and Practice **2017**, 129-182		
9	Capsule commentary on Mukhtar et al., Assessment of HBV preventive services in a medically underserved Asian and Pacific Islander population using provider and patient data. *Journal of General Internal Medicine*, **2015**, 30, 866	4	
8	p53 Autoantibodies **2014**, 289-294		

7	Tumor Immunology **2007**, 137-149	
6	S0984 Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. *American Journal of Gastroenterology*, **2020**, 115, S501-S502	0.7
5	Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases. *Gastroenterology and Hepatology*, **2020**, 16, 31-38	0.7
4	Primary and Secondary Sclerosing Cholangitis **2018**, 626-647.e6	
3	Diagnostic Liver Immunology **2020**, 139-150	
2	Diagnostic Liver Immunology **2014**, 45-53	
1	Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis. *Clinical Epidemiology*, **2020**, 12, 1261-1267	5.9